ties have been discovered, requiring an update of the classification in 1995, 3 and the aetiology of many forms has been clarified.
The Working Group of Myocardial and Pericardial Disease of the European Society of Cardiology (ESC) recently published a position statement 4 different from the 2006 American Heart Association (AHA) scientific statement. 5 The scope of the present editorial is to deal with the nosographic impact of the advances made since 1995 and to comment on the ESC position statement which has been designed to provide a valid tool for routine clinical practice.
Revision of the definition and classification of cardiomyopathies in 1995
The discovery of novel cardiomyopathies, namely arrhythmogenic right ventricular cardiomyopathy (ARVC), primary restrictive cardiomyopathy, and non-compacted myocardium, made a revision of the 1980 classification compulsory, and this led to many substantial, though often questionable, changes. 3 Moreover, taking into consideration that the aetiology was becoming clearer and clearer, the definition was changed from 'heart muscle disease of unknown aetiology' into 'myocardial disease associated with cardiac dysfunction', the term dysfunction meaning both mechanical and electrical abnormality. In the new classification, ARVC 6, 7 and restrictive cardiomyopathy 8 were added to the primary forms, whereas the non-compacted myocardium was left in the limbo of 'unclassified cardiomyopathies'. The secondary forms, which in the classification of the 1980s were called specific heart muscle diseases, were given the name of 'specific cardiomyopathies', and within this group myocarditis was added. Unfortunately, the concept of specific cardiomyopathy was widened too much, so as to include chronic ischaemic, valvular, and hypertensive diseases.
Although the 1995 classification made significant contributions (acknowledging new entities, unifying terminology, including myocarditis), nonetheless it introduced ambiguities by classifying the ischaemic and overload disorders among the cardiomyopathies.
Understanding the molecular mechanisms of cardiomyopathies
Besides taxonomic and nosographic improvements, mostly of an etymological and semantic nature, the great advances in the field of cardiomyopathies came from the rapid revolution of molecular biology in cardiology.
In inflammatory cardiomyopathy, the use of in situ hybridization and polymerase chain reaction (PCR) demonstrated that not only enteroviruses, but also adenoviruses are cardiotropic. 9 Moreover, molecular biology made fundamental steps forward in understanding the genetics of cardiomyopathies. About onethird of dilated cardiomyopathies are heredo-familial, frequently
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. associated with skeletal muscle or neuromuscular disorders. Gene defects of familial dilated cardiomyopathy (either autosomal or Xlinked) code for proteins such as dystrophin and associated glycoproteins, sarcoglycans, and destroglycans, all cytoskeleton proteins concerned with force transmission. 10 For this reason, familial dilated cardiomyopathy is reported as a disease of the cytoskeleton. 10, 11 The same dilated cardiomyopathy, which results from enteroviral myocarditis, finds a molecular explanation as a sequela of the lytic action of viral protease 2A on the dystrophin complex.
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Hypertrophic cardiomyopathy, an heredo-familial disease with autosomal dominant Mendelian transmission, has been demonstrated to be essentially a sarcomere disease with a disorder of force generation, since the defective genes encode contractile proteins such as b-myosin heavy chain, myosin-binding protein C, atropomyosin, and troponin T and I. 13 Also primary restrictive cardiomyopathy, a dominant autosomal disease, has been proven to be a sarcomere disease, since troponin I gene mutations have been identified. It is reasonable that the abnormal protein impairs the relaxation of the myofilaments during diastole, accounting for restrictivity. ARVC, an autosomal dominant but also a recessive disorder, was shown to be a cell junction disease, namely of the desmosomes ensuring mechanical attachments between cardiomyocytes.
14 Deletions or mutations have indeed been reported in the genes encoding desmoplakin, plakoglobin, plakophilin, desmoglein, and desmocollin. Mechanical stretch of the thin right ventricular wall may account for desmosomal disruption, cell injury, and repair with fibrofatty replacement. The definition as diseases of the myocardium associated with cardiac dysfunction widens the concept of cardiomyopathies. Classically, dysfunction of the cardiomyocyte was thought to be contractile in nature: this is the case for dilated cardiomyopathy, with systolic pump failure; hypertrophic cardiomyopathy, with even enhanced systolic contractility; and restrictive cardiomyopathy, with impaired diastolic relaxation. However, myocardial dysfunction can be purely electric, as is the case for both structural (i.e. myocarditis, ARVC) and non-structural heart muscle disease (i.e. ion channel diseases), in the absence of any contractile impairment.
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Long and short QT syndromes are mostly characterized by mutation of K þ channel genes; Brugada syndrome and Lenègre disease by mutations of the Na þ channel gene (SNC5A); and catecholaminergic polymorphic ventricular tachycardia by mutations of ryanodine receptor 2, which controls the Ca 2þ release from the sarcoplasmic reticulum. With the exception of Lenègre disease, an elective cardiomyopathy of the specialized conduction system, all these syndromes are associated with a structurally normal heart, and the patient's vulnerability resides in the electrical instability at the myocyte membrane. The alteration is seen only on the ECG: QT lengthening or shortening, ST segment elevation, or effort-induced ventricular tachycardia, respectively. The substrate is at the molecular level where a simple missense mutation may determine an abnormal sequence of the nucleotide triplet encoding an amino acid, with a change in the corresponding protein.
Thus primary inherited cardiomyopathies might be distinguished into two categories: 11 (i) cardiomyopathies with structural abnormalities (dilated, hypertrophic, restrictive, and arrhythmogenic) ¼ cytoskeleton, sarcomeric, cell junction diseases; and (ii) cardiomyopathies without structural abnormalities (short and long QT, Brugada, and catecholaminergic polymorphic ventricular tachycardia) ¼ channelopathies. By accepting the view that cardiomyopathy may manifest only with an electric disorder, in the absence of structural abnormalities, we recognize that these cardiomyopathies can be diagnosed more by ECG than by echo or other cardiac imaging techniques.
AHA scientific statement
The AHA has recently incorporated these ideas in a Scientific Statement, 5 advancing a new definition and classification. If cardiac dysfunction can be both mechanical and electrical, then a cardiomyopathic heart does not necessarily appear dilated or hypertrophic, and the causes are several, both genetic and acquired. Accordingly, the following definition has been put forward. 'Cardiomyopathies are a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently are genetic'. The original distinction into primary and secondary forms was reintroduced, considering primary cardiomyopathies 'those solely or predominantly confined to heart muscle' and secondary those with 'myocardial involvement as part of generalized systemic (multiorgan) disorders'. Primary cardiomyopathies have been divided into three main categories (genetic, acquired, and mixed), incorporating among genetic also primary electrical disorders with a structural normal heart (channelopathies). Lenègre disease was considered a cardiomyopathy, and the group of unclassified cardiomyopathies was abolished. A subclassification of cardiomyopathies into familial/genetic and non-familial/non-genetic was considered of help in orienting towards genetic mutational analysis and screening. Thus, the concept of cardiomyopathy has evolved into the current perspective of a larger group of genetically determined diseases of the myocyte, that includes not only the previously recognized conditions manifesting as overt morphofunctional cardiac abnormalities, but also new conditions showing a primarily arrhythmic phenotype, in the absence of structural changes. There is growing evidence that these 'primarily electrical' cardiomyopathies often show an overlap with phenotypic manifestations of 'traditional structural' cardiomyopathies. 15 The AHA Task Force proposed a 'beyond of phenotype' classification of cardiomyopathies, that groups under such a designation all myocardial diseases, whose common denominator is a genetic defect, consisting of mutant genes encoding sarcomeric, cytoskeletal, desmosomal, or ion channel proteins.
ESC position statement
An update of the 1995 WHO/ISFC classification has also been proposed as a position statement of the ESC Working Group on Myocardial and Pericardial diseases and recently published. 4 In the definition, it is clearly stated that cardiomyopathy is 'a myocardial disorder in which heart muscle is structurally and functionally abnormal in the absence of coronary artery disease, hypertension, valvular disease, and congenital heart diseases'.
While accepting and reinforcing the idea advanced by the AHA statement to divide cardiomyopathies into familial/genetic and nonfamilial/non-genetic, the traditional division of primary and secondary (specific) cardiomyopathies was abolished, probably with the erroneous belief that primary means idiopathic and secondary means of known aetiology. Moreover, the concept of pure electrical dysfunction was denied, thus ruling out ion channel and conduction system diseases from the umbrella of cardiomyopathies.
Basically, five types of cardiomyopathies are recognized according to the morphofunctional phenotype (hypertrophic, dilated, arrhythmogenic, restrictive, and unclassified), either familial or non-familial, whether or not the heart is the only target of the disease.
This approach is certainly a simplification of a complex nosographic puzzle, but does not yet fully answer the question raised by emerging evidence. While removal of specific cardiomyopathies such as ischaemic, hypertensive, and valvular should be greeted with cheers, as the AHA document first did in 2006, it is not convincing at all why myocarditis should be grouped 'tout court' among dilated cardiomyopathies. What about acute/fulminant myocarditis or those presenting only with arrhythmias and chest pain? The AHA position statement abolished the so-called nonclassified cardiomyopathies, whereas the ESC position statement still regards forms such as non-compaction and Tako Tsubo in search of a room. Finally, only cardiomyopathies with structural deformities were included, renewing the purely morphofunctional approach, without considering the problem of possible evolution of a disease phenotype into another during the natural history and leaving electrical disorders without a taxonomic location.
Conclusions
Both the AHA and ESC statements are commendable contributions which certainly help to clarify this complex field. The concept of electrical cardiomyopathy due to ion channel diseases remains a major concern, because theoretically it might be extended from ventricles to atria so as to include familial atrial fibrillation among inherited cardiomyopathies.
We are well aware of the complexity of disease phenotype in the setting of a nosographic framework and of the risk of overlap among categories. However, an agreement to update the 1995 WHO/ISFC classification is deemed necessary, with merging views of worldwide scientists, based upon the breaking news coming from genomics and proteomics of molecular cardiovascular medicine.
